Navigation Links
Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone
Date:1/27/2010

BANGALORE, India, January 27 /PRNewswire-FirstCall/ -- Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals ( ENDP)., of Chadds Ford, Pa., U.S.A., announced today that they have expanded their drug discovery partnership in oncology, following the successful delivery of an early stage milestone.

The year-old partnership focuses on Jubilant delivering preclinical candidates in the therapeutic area of oncology. Endo owns the late-stage development and commercialization rights for molecules discovered in the partnership. Jubilant derives research funding and success-based development and commercialization milestones.

Commenting on this development, Sri Mosur, CEO & President, Global Drug Discovery & Development said: "We are pleased that we could deliver early success to the discovery portfolio efforts at Endo Pharmaceuticals and this expansion is a testimony to Jubilant's focus in building world class oncology capabilities, among other therapeutic areas. This collaboration further reinforces the concept of globally leveraged R&D that creates a platform for scientists from Endo and Jubilant to collaborate in finding affordable remedies for cancer patients worldwide."

"We have been impressed by the quality of the science and the progress made to date by the Jubilant team on our ongoing oncology discovery program, said Dr. Ivan Gergel, M.D, Executive Vice President of R&D at Endo Pharmaceuticals. "Expanding our relationship in this important therapeutic area is consistent with our strategy of building Endo's pipeline using a virtual discovery approach, in conjunction with our in-licensing efforts."

About Jubilant Biosys

Jubilant Biosys Ltd. (JBL) (www.jubilantbiosys.com), a subsidiary of Jubilant Organosys Ltd., provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has an integrated state of the art facility in Bangalore. The Center houses over 450 scientists specializing in multiple disciplines to include Discovery biology, medicinal chemistry, structural biology, pharmacology, toxicology, pharma chem, molecular modeling, crystallography and information technology supporting discovery efforts.

About Jubilant Organosys Limited

Jubilant Organosys Ltd., headquartered at Noida, an integrated pharmaceutical industry player, is India's largest Custom Research and Manufacturing Services company (CRAMS) and a leading Drug Discovery and Development Solution Provider. The company has a presence across the pharmaceutical value chain for providing products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables & non-steriles products, radiopharmaceuticals, generic dosage forms, drug discovery services, medicinal chemistry services, clinical research services, and Health Care. The Company also manufactures Industrial and Performance products. http://www.jubl.com

Disclaimer:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company's filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

    For Business Queries
    Kailash Swarna
    Sr. VP and COO,
    Jubilant Drug Discovery and Development
    kailash_swarna@jubilantbiosys.com

    For Media
    Seema Ahuja
    VP-Corporate Marketing & Communications
    Jubilant Organosys Ltd
    +919810631779,
    seema_ahuja@jubl.com

SOURCE Jubilant Biosys Ltd


'/>"/>
SOURCE Jubilant Biosys Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Jubilant and BioLeap Announce New Partnership in Drug Discovery
2. Jubilant Biosys Launches Legend NGSS(TM) Advanced Software Solution for High-Throughput Drug Molecule Screening
3. Jubilant to Work With Endo Pharmaceuticals on Drug Development
4. DiscoveRx Corp. & Jubilant Biosys Limited Announce Co-Marketing Agreement for Screening Services
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
9. ConforMIS Moves Headquarters to Expanded Facilities in Burlington, MA
10. BioLife Solutions Expands Scientific Advisory Board
11. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2017)... ... June 19, 2017 , ... As Vice ... EDETEK’s products including training, implementation, support, and client process and SOP development. , ... has previously held leadership roles for service providers and top-tier pharmaceuticals, and as ...
(Date:6/16/2017)... ... June 16, 2017 , ... Cambridge ... announced that its Anzo Smart Data Lake® (Anzo SDL) solution was named ... the 2017 Software & Information Industry Association (SIIA) CODiE Awards. , Finalists ...
(Date:6/15/2017)... ... June 15, 2017 , ... angelMD announced the closure of ... Parsley, angelMD’s SVP of Corporate Development, served as the syndicate leader for this ... of Saranas’ recently announced $4 million Series B financing round. , Saranas is ...
(Date:6/14/2017)... , ... June 14, 2017 , ... ... materials for pumps and process equipment, has appointed Andrew Ondish as Territory Sales ... Ondish holds a B.S. degree in Petroleum Engineering from Colorado School of Mines. ...
Breaking Biology Technology:
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):